AstraZeneca PLC's externalization strategy in the future will probably engage more in partnering collaborations with other drug makers that generate recurring revenue and focus less on the sell-off of mature therapies that don’t fit the pharma’s pipeline strategy, Head of Business Development Shaun Grady told Scrip.
AstraZeneca’s business development approach comprises a three-pronged strategy, the first of which is known within the company as “externalization” and...








